In a recent study published in Nature Communications , researchers investigated the effects of statins via inhibition of interleukin 33 (IL-33). This epithelial-derived alarmin cytokine promotes chronic inflammation by activating type 2 immune responses associated with chronic inflammatory disorders. Study: Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression .
Image Credit: roger ashford/Shutterstock.com Chronic inflammation is a primary cause of cancer globally, with illnesses such as inflammatory bowel disease (IBD), pancreatitis, and hepatitis becoming more prevalent. Immunological factors and cells such as mast cells, M2 macrophages, interleukin-10, interleukin-13, and tumor growth factor beta (TGF-β) contribute to carcinogenesis.
Inhibiting effector molecules to prevent cancers is difficult, given their involvement in cancer promotion. Anti-inflammatory medicines, such as dexamethasone, have serious adverse effects, making it critical to discover safe molecules to reduce chronic inflammatory reactions and avoid cancer complications. IL-33 is a primary initiator of cancer-causing chronic inflammation, although its mechanism remains unexplained.
In the present study, researchers investigated the potential of IL-33 and its receptor ST2 as targets for disrupting the chronic inflammatory milieu associated with disorders such as inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), hepatitis, and pancreatitis. T.
